article thumbnail

AAFP Represents Members During 2025 Legislative Session

Alabama Academy of Family Physicians

The 2025 Alabama Legislative Session concluded on May 14 at midnight. Pharmacy benefits managers would be prohibited under this bill from barring disclosure of information by pharmacists to consumers about drug costs and alternative drugs for treatment. What Happened: The bill was signed into law by the Governor on 4/15/2025.

Insurance 130
article thumbnail

MN Legislative Session 2025: Updates on Health Care Bills

Minnesota Academy of Family Physicians

SENATE HEALTH AND HUMAN SERVICES (HHS) COMMITTEE On Tuesday, March 18, 2025, the Senate HHS Committee heard a series of health care bills: S.F. 2403 ( Representative O’Driscoll ): On Wednesday, March 19, 2025, the House Commerce Finance and Policy Committee heard H.F. Highlights follow. Read a summary of S.F. Read a summary of S.F.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Green Practice News: May 2025

My Green Doctor

This financial predictability allows for better budgeting and resource allocation.​ – Reduced Operational Costs : Implementing energy-efficient technologies, such as LED lighting and automated energy management systems, can decrease energy consumption by up to 30%, leading to further cost reductions. ​ The use of medications in U.S.

article thumbnail

Revised Final Guidance on Nitrosamines Offers New Recommendations for Assessment and Control

FDA Law Blog

Nitrosamines are impurities that can form during drug manufacturing and are considered potentially potent carcinogens. It’s these varied scenarios that give quality managers nightmares. The revisions due in 2025 include testing for NDSRIs. Using the guidelines found in the ICH M7(R2) , FDA set an AI threshold of 1.5

article thumbnail

Researchers Propose Solutions to Improve GLP-1 RA Access

Physician's Weekly

Cost-sharing interventions and patient education can help improve access to GLP-1 receptor agonists for patients with obesity, according to an abstract presented at the AACE Annual Meeting 2025. Health is a social good, and thus society has an obligation to provide health services that address the needs of all.

article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

FDA Law Blog

Since 2019, when DPD took over this process, the Division has published more than 600 ANDA withdrawals at the request of generic drug manufacturers. Managing the process of issuing Covered Product Authorizations (CPAs) under the CREATES Act. Providing significant policy support to the annual update of the Orange Book Preface.

IT 144
article thumbnail

A Chihuahua or a Muffin? FDA Announces Plans for Aggressive Use of Artificial Intelligence

FDA Law Blog

Javitt On May 8, 2025, FDA announced the successful completion of a generative artificial intelligence (AI) scientific review pilot program aimed at accelerating the review process and an aggressive timeline to rollout the use of AI tools across the Agency. By Adrienne R. Lenz, Principal Medical Device Regulation Expert & Lisa M.